Microbiotica
Microbiome therapeutics, Cambridge
Wellcome Sanger spinout developing live bacterial therapeutics for cancer and ulcerative colitis. It raised £36m in its Series C in October 2026. We can't read its job board yet.
Not found on the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
All 17 stories- OtherPharmaTimes, 6 days agoMicrobiotica presents phase 1b data for MB097 at ESMO 2026
- OtherPluang, 7 days agoMicrobiotica's MB097 shows safety and promising efficacy in advanced melanoma Phase 1b trial with KEYTRUDA.
- OtherBusiness Weekly, 7 days agoMicrobiotica reigns in Spain as MELODY clinical trial data for advanced melanoma hits right note
- FundingCambridge Independent, 11 days agoMicrobiotica’s £36m Series C raise validates microbiome approach
- OtherInfotechLead, 16 days agoVC funding deals: Estuary Biotherapeutics, Microbiotica, Undecimal Bio
- OtherProactive financial news, 17 days agoMicrobiotica CEO on £36m raise to advance gut treatment into Phase 2; IP Group invests £4m